Scleroderma Renal Crisis
A 30-year-old woman with 8 months of rapidly progressive skin thickening, Raynaud phenomenon, and positive anti-RNA polymerase III antibodies has 4 days of severe headache and blurred vision. Blood pressure is 196/114 mm Hg, having been 120/70 mm Hg 2 months ago. Serum creatinine is 238 µmol/L, up from 68 µmol/L, hemoglobin 9.2 g/dL with schistocytes, and platelets 88 × 10⁹/L. What is the most appropriate treatment?
- A.Atenolol
- B.CaptoprilCorrect
- C.Hydrochlorothiazide
- D.Verapamil
Explanation
This is scleroderma renal crisis, and a short-acting angiotensin-converting enzyme inhibitor such as captopril, titrated rapidly to control blood pressure, is the treatment of choice and the intervention that transformed this once uniformly fatal complication into a survivable one. Scleroderma renal crisis occurs mainly in early diffuse cutaneous systemic sclerosis, particularly with anti-RNA polymerase III antibodies and recent high-dose corticosteroid exposure, and results from intimal proliferation and narrowing of interlobular renal arteries. The resulting renal hypoperfusion triggers massive renin release, so angiotensin II drives malignant hypertension and further vasoconstriction, and the narrowed vessels shear red cells to produce a microangiopathic hemolytic anemia with thrombocytopenia. Blocking the renin-angiotensin axis interrupts this loop directly, and ACE inhibitors are continued even if creatinine rises initially or dialysis is needed, because renal function can recover over months. Beta blockers reduce renin release only modestly and their negative inotropic and peripheral vasoconstrictive effects can aggravate Raynaud phenomenon and digital ischemia. Thiazides are ineffective in severe hypertension with renal impairment and further reduce intravascular volume, which worsens renal hypoperfusion. Calcium channel blockers help Raynaud phenomenon and may be added for residual hypertension but do not address the renin-driven mechanism, so they are never used as the primary agent. Note also that angiotensin receptor blockers are not equivalent substitutes in this specific setting and prophylactic ACE inhibition does not prevent renal crisis.
Why each option
- A.
- Beta blockers can worsen Raynaud phenomenon and digital ischemia and do not address the renin-mediated mechanism of renal crisis.
- B.
- Correct. A short-acting ACE inhibitor directly interrupts the renin-angiotensin cascade driving scleroderma renal crisis and improves renal and overall survival.
- C.
- Thiazides are weak antihypertensives in renal impairment and worsen renal hypoperfusion by reducing intravascular volume.
- D.
- Calcium channel blockers are useful for Raynaud phenomenon and as add-on therapy but never as first-line treatment of renal crisis.
Reference: EULAR Recommendations for the Treatment of Systemic Sclerosis, 2017 update; UpToDate 2025, Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis
This is one of 3,009 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank